Dermapharm Holding SE (DMP) — Capital Reinvestment Ratio
Dermapharm Holding SE (DMP) has a Capital Reinvestment Ratio of 0.30x as of March 2026, meaning it reinvests 0% of its operating cash flow (€39.49 Million) in capital expenditures (€11.85 Million). Check DMP tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Dermapharm Holding SE Capital Reinvestment Ratio (2014–2025)
This chart tracks Dermapharm Holding SE's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Dermapharm Holding SE.
Annual Capital Reinvestment Ratio for Dermapharm Holding SE (2014–2025)
Year-by-year Capital Reinvestment Ratio for Dermapharm Holding SE from 2014 to 2025. See Dermapharm Holding SE free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | €181.51 Million | €42.12 Million | ▲ +22.2% |
| 2024 | 0.19x | €201.38 Million | €38.24 Million | ▲ +0.3% |
| 2023 | 0.19x | €219.42 Million | €41.54 Million | ▲ +40.0% |
| 2022 | 0.14x | €288.53 Million | €39.01 Million | ▼ -44.7% |
| 2021 | 0.24x | €250.37 Million | €61.20 Million | ▼ -21.4% |
| 2020 | 0.31x | €131.10 Million | €40.80 Million | ▼ -32.6% |
| 2019 | 0.46x | €100.61 Million | €46.44 Million | ▲ +182.8% |
| 2018 | 0.16x | €159.13 Million | €25.97 Million | ▼ -81.1% |
| 2017 | 0.86x | €86.74 Million | €74.72 Million | ▲ +272.4% |
| 2016 | 0.23x | €76.78 Million | €17.76 Million | ▼ -37.5% |
| 2015 | 0.37x | €40.38 Million | €14.93 Million | ▼ -29.4% |
| 2014 | 0.52x | €54.26 Million | €28.42 Million | — |